SIRT1 and breast carcinoma: SIRT1 inhibition was reported to reduce both the nuclear FOXO1 levels and MRP2 expression while enhancing cytotoxic effects of paclitaxel and doxorubicin in tamoxifen-resistant breast cancer cells.